과제정보
이 논문은 2023학년도 원광대학교의 교비지원에 의해 수행됨
참고문헌
- Slatore C, Lareau SC, Fahy B. Staging of Lung Cancer. Am J Respir Crit Care Med. 2022;205(9):17-19.
- Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379-92.
- Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29(3):1828-39.
- Zhu T, Bao X, Chen M, Lin R, Zhuyan J, Zhen T, et al. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis. Front Oncol. 2020;10:585284.
- Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J Thorac Dis. 2011;3(1):19-29.
- Islam KM, Anggondowati T, Deviany PE, Ryan JE, Fetrick A, Bagenda D, et al. Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. BMC Cancer. 2019;19(1):835.
- Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15(1):18.
- Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med. 2008;14(5):199-209.
- Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156-72.
- Takeda Y, Naka G, Yamaguchi Y, Hashimoto M, Suzuki M, Izumi S, et al. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. BMC Cancer. 2020;20(1):951.
- Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044.
- Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8.
- Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fbrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525-34.
- Lee KT, Choi J, Jung WT, Nam JH, Jung HJ, Park HJ. Structure of a new echinocystic acid bisdesmoside isolated from Codonopsis lanceolata roots and the cytotoxic activity of prosapogenins. J Agric Food Chem. 2002;50(15):4190-3.
- Hossen MJ, Kim MY, Kim JH, Cho JY. Codonopsis lanceolata: A Review of Its Therapeutic Potentials. Phytother Res. 2016;30(3):347-56.
- Yoo HH, Baek SH, Park YK, Lee SH, Kim CM, Lee KS, et al. Quality control of dried roots of Codonopsis lanceolata. Kor J Pharmacogn. 2002;33(2):85-7.
- Han EG, Sung IS, Moon HG, Cho SY. Effect of Codonopsis lanceolata water extract on the levels of lipid in rats fed high fat diet. J Korean Soc Food Sci Nutr. 1998;27:940-4.
- Wang MC, Wu YF, Yu WY, Yu B, Ying HZ. Polyacetylenes from Codonopsis lanceolata Root Induced Apoptosis of Human Lung Adenocarcinoma Cells and Improved Lung Dysbiosis. Biomed Res Int. 2022;2022:7713355.
- Byeon SE, Choi WS, Hong EK, Lee J, Rhee MH, Park HJ, et al. Inhibitory effect of saponin fraction from Codonopsis lanceolata on immune cell-mediated inflammatory responses. Arch Pharm Res. 2009;32(6):813-22.
- Xu LP, Wang H, Yuan Z. Triterpenoid saponins with anti-inflammatory activity from Codonopsis lanceolata. Planta Med. 2008;74(11):1412-5.
- Du YE, Lee JS, Kim HM, Ahn JH, Jung IH, Ryu JH, Choi JH, Jang DS. Chemical constituents of the roots of Codonopsis lanceolata. Arch Pharm Res. 2018;41(11):1082-91.
- Lv P, Man S, Xie L, Ma L, Gao W. Pathogenesis and therapeutic strategy in platinum resistance lung cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188577.
- Chen JA, Riess JW. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2020;12(5):2859-76.
- Li Z, Feiyue Z, Gaofeng L. Traditional Chinese medicine and lung cancer--From theory to practice. Biomed Pharmacother. 2021;137:111381.
- Ni M, Wang H, Wang M, Zhou W, Zhang J, Wu J, et al. Investigation on the Efficiency of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Vinorelbine and Cisplatin Based on Multidimensional Bayesian Network Meta-Analysis. Front Pharmacol. 2021;11:631170.
- Chen RL, Wang Z, Huang P, Sun CH, Yu WY, Zhang HH, et al. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice. Int Immunopharmacol. 2021;94:107357.
- Joh EH, Hollenbaugh JA, Kim B, Kim DH. Pleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer target. PLoS One. 2012;7(11):e50424.
- Du YE, Lee JS, Kim HM, Ahn JH, Jung IH, Ryu JH, et al. Chemical constituents of the roots of Codonopsis lanceolata. Arch Pharm Res. 2018;41(11):1082-91.
- Li W, Xu Q, He YF, Liu Y, Yang SB, Wang Z, et al. Anti-Tumor Effect of Steamed Codonopsis lanceolata in H22 Tumor-Bearing Mice and Its Possible Mechanism. Nutrients. 2015;7(10):8294-307.
- Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587-629.
- Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(3):511-8.
- Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen LK. Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviour in the PI3K/mTOR Signalling Network. Int J Mol Sci. 2021;22(13):6944.
- Conciatori F, Bazzichetto C, Falcone I, Ciuffreda L, Ferretti G, Vari S, et al. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. Int J Mol Sci. 2020;21(15):5337.
- Kang BW, Chau I. Molecular target: pan-AKT in gastric cancer. ESMO Open. 2020;5(5):e000728.
- Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020;13(6):100773.
- Ahn JH, Jang DS, Choi JH. Lancemaside A Isolated from the Root of Codonopsis lanceolata Inhibits Ovarian Cancer Cell Invasion via the Reactive Oxygen Species (ROS)-Mediated p38 Pathway. Am J Chin Med. 2020;48(4):1021-34.
- Liu Y, Zou X, Sun G, Bao Y. Codonopsis lanceolata polysaccharide CLPS inhibits melanoma metastasis via regulating integrin signaling. Int J Biol Macromol. 2017;103:435-40.
- So J, Kim J. Effects of Codonopsis lanceolata extracts on bFGF-induced angiogenesis in vitro. Korean J Biotechnol Bioeng. 2003;18(1):25-9.
- Lee SY, Ju MK, Jeon HM, Lee YJ, Kim CH, Park HG, et al. Reactive oxygen species induce epithelial‑mesenchymal transition, glycolytic switch, and mitochondrial repression through the Dlx‑2/Snail signaling pathways in MCF‑7 cells. Mol Med Rep. 2019;20(3):2339-46.
- Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer. 2010;1(5):409-20.
- Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9(4):317-24.
- Wu W, Wang Y, Li H, Chen H, Shen J. Buyang Huanwu Decoction protects against STZ-induced diabetic nephropathy by inhibiting TGF-β/Smad3 signaling-mediated renal fibrosis and inflammation. Chin Med. 2021;16(1):118.
- Zhang L, Zhou F, ten Dijke P. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci. 2013;38(12):612-20.
- Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33(1):62.
- Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.
- Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One. 2013;8(3):e57692.
- Weng CH, Chen LY, Lin YC, Shih JY, Lin YC, Tseng RY, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019;38(4):455-68.